(Albany, United States) As per DelveInsight’s assessment, globally, the Chronic Obstructive Pulmonary Disease pipeline constitutes 65+ key companies continuously working towards developing 70+ Chronic Obstructive Pulmonary Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
To explore more information on the latest breakthroughs in the Chronic Obstructive Pulmonary Disease Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight
Key Takeaways from the Chronic Obstructive Pulmonary Disease Pipeline Report
- DelveInsight’s Chronic Obstructive Pulmonary Disease Pipeline analysis depicts a robust space with 65+ active players working to develop 70+ pipeline treatment therapies.
- The leading Chronic Obstructive Pulmonary Disease Companies are working in the market include Sanofi, AstraZeneca, Amgen, Synairgen, GlaxoSmithKline, Eisai, Meridigen Biotech, Chiesi, EmeraMed Limited, Verona Pharma, Tetherex Pharmaceuticals, Mereo BioPharma, and others
- Promising Chronic Obstructive Pulmonary Disease Pipeline Therapies in the various stages of development include Astegolimab, REGEND001 Autologous Therapy Product, High dose or normal dose staphylococcus albicans, Ensifentrine, Benralizumab, Tiotropium Bromide Combined With Odaterol, and others.
- February 2024:- GlaxoSmithKline- A Prospective, Epidemiological, Cohort Study to Assess the Aetiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Japan. The purpose of this prospective, epidemiological, cohort study is to evaluate the lung microbiome in stable-state chronic obstructive pulmonary disease (COPD) in Japanese participants
- January 2024:- University of Noth Carolina, Chapel- Use of ProAir Digihaler in Chronic Obstructive Pulmonary Disease (COPD) – Characterization of Inhalation Metrics From a Cohort of Patient At-risk for Acute Exacerbation of COPD (AECOPD) in an Outpatient Setting. This is a multi-center 3-month study to determine the variation in ProAir Digihaler metrics [peak inspiratory flow (PIF), inhalation volume, number of inhalation events] amongst COPD patients in the ambulatory setting.
Chronic Obstructive Pulmonary Disease Overview
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease. It is a poorly reversible lung disease characterized by persistent and progressive airflow limitation caused by an enhanced chronic inflammatory response in the airways and the lungs due to noxious particles or gases.
For further information, refer to the detailed Chronic Obstructive Pulmonary Disease Unmet Needs, click here for Chronic Obstructive Pulmonary Disease Ongoing Clinical Trial Analysis @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight
Chronic Obstructive Pulmonary Disease Emerging Drugs Profile
- Benralizumab: AstraZeneca
- Dupilumab: Sanofi
- Tezepelumab: Amgen
- SNG001: Synairgen
- GSK3923868: GlaxoSmithKline
Chronic Obstructive Pulmonary Disease Pipeline Therapeutics Assessment
There are approx. 65+ Chronic Obstructive Pulmonary Disease companies which are developing the therapies for Chronic Obstructive Pulmonary Disease. The Chronic Obstructive Pulmonary Disease companies which have their Chronic Obstructive Pulmonary Disease drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.
Request a sample and discover the recent advances in Chronic Obstructive Pulmonary Disease Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight
Chronic Obstructive Pulmonary Disease Drugs and Companies
- Endo Pharmaceuticals: Trospium Chloride Inhalation Power
- AstraZeneca: Roflumilast
- Mylan Inc: TD-4208 700 pg
- Viatris Inc: Ipratropium 500 pg
- Astellas Pharma Inc: Reldesemtiv
- Nuance Pharma Co. Ltd: Ensifentrine
- Sanofi: Itepekimab SAR440340
Chronic Obstructive Pulmonary Disease Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Chronic Obstructive Pulmonary Disease Therapeutics Market include-
Sanofi, AstraZeneca, Amgen, Synairgen, GlaxoSmithKline, Eisai, Meridigen Biotech, Chiesi, EmeraMed Limited, Verona Pharma, Tetherex Pharmaceuticals, Mereo BioPharma, and others.
Dive deep into rich insights for drugs for Chronic Obstructive Pulmonary Disease Pipeline, click here for Chronic Obstructive Pulmonary Disease Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight
Scope of the Chronic Obstructive Pulmonary Disease Pipeline Report
- Coverage- Global
- Chronic Obstructive Pulmonary Disease Companies- Sanofi, AstraZeneca, Amgen, Synairgen, GlaxoSmithKline, Eisai, Meridigen Biotech, Chiesi, EmeraMed Limited, Verona Pharma, Tetherex Pharmaceuticals, Mereo BioPharma, and others.
- Chronic Obstructive Pulmonary Disease Therapies- Astegolimab, REGEND001 Autologous Therapy Product, High dose or normal dose staphylococcus albicans, Ensifentrine, Benralizumab, Tiotropium Bromide Combined With Odaterol, and others
- Chronic Obstructive Pulmonary Disease Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Chronic Obstructive Pulmonary Disease Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight
Table of Content
- Introduction
- Executive Summary
- Chronic Obstructive Pulmonary Disease: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Chronic Obstructive Pulmonary Disease– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Benralizumab: AstraZeneca
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Tezepelumab: Amgen
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- GSK3923868: GlaxoSmithKline
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Chronic Obstructive Pulmonary Disease- Unmet Needs
- Chronic Obstructive Pulmonary Disease- Market Drivers and Barriers
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/